Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

2.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.7K
Asthma-I: Introduction01:29

Asthma-I: Introduction

2.6K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.6K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

396
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
396
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

294
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
294
Asthma-III: Symptoms and Complications01:24

Asthma-III: Symptoms and Complications

2.5K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
2.5K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

The use of JAK inhibitors and tocilizumab in the management of TRAPS: a sibling case study.

Pediatric rheumatology online journal·2026
Same author

NK cell dysfunction and interferon-γ production underlie autoinflammation in mevalonate kinase deficiency.

Immunity·2026
Same author

Single-cell profiling of BAL in preschool cystic fibrosis reveals macrophage dysregulation and ivacaftor-modified inflammatory programs in the early life lung.

Mucosal immunology·2026
Same author

Comparative performance of common paediatric patient-reported outcome measures (P-PROMs) across health conditions.

Archives of disease in childhood·2026
Same author

Macrophages orchestrate antiviral defense and epithelial repair in a human iPSC-derived alveolar air-liquid interface.

JCI insight·2026
Same author

Antibody responses against bacterial glycans affinity mature and diversify in germinal centers.

Immunity·2026

相关实验视频

Updated: Jul 1, 2025

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis
03:23

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis

Published on: May 10, 2024

749

湿和喘息:超越喘的思考

Stephanie L Kuek1, Colin Pettman2, Melanie R Neeland3,4

  • 1Respiratory and Sleep Medicine, Royal Children's Hospital, Melbourne, Australia.

Breathe (Sheffield, England)
|March 14, 2024
PubMed
概括

初级异常性过敏氨基酸性综合征是一种罕见的疾病,会导致器官损伤. 梅波利祖马布提供了一种安全,有效的治疗方法,减少了对类固醇的需求.

更多相关视频

Methodology for Sputum Induction and Laboratory Processing
13:28

Methodology for Sputum Induction and Laboratory Processing

Published on: December 17, 2017

27.6K
Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation
08:44

Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation

Published on: May 30, 2020

6.1K

相关实验视频

Last Updated: Jul 1, 2025

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis
03:23

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis

Published on: May 10, 2024

749
Methodology for Sputum Induction and Laboratory Processing
13:28

Methodology for Sputum Induction and Laboratory Processing

Published on: December 17, 2017

27.6K
Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation
08:44

Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation

Published on: May 30, 2020

6.1K

科学领域:

  • 血液学 血液学 血液学
  • 免疫学 免疫学 免疫学
  • 罕见疾病 罕见疾病

背景情况:

  • 初级异常性高氨酸性综合征 (HES) 是一种罕见的克隆性疾病.
  • 它的特点是持续的乙亲症和潜在的末端器官损伤.
  • 目前的治疗方法通常涉及皮质类固醇,具有显著的副作用.

研究的目的:

  • 评估梅波利祖马布在治疗原发性异常性HES患者中的疗效和安全性.
  • 评估mepolizumab在这个患者群体中的类固醇节约潜力.

主要方法:

  • 进行了一项临床研究,涉及诊断为原发性异常性HES的患者.
  • 患者接受了一种向单克隆抗体 - - 梅波利祖马布.
  • 测量结果包括临床反应,器官损伤标志物和皮质类固醇剂量.

主要成果:

  • 梅波利祖马布在管理HES方面表现出显著的临床疗效.
  • 观察到皮质类固醇依赖的显著减少.
  • 治疗一般耐受良好,具有良好的安全性.

结论:

  • 梅波利祖马布 (Mepolizumab) 是一种安全有效的针对性治疗,用于原发性异常性HES.
  • 它提供了一种有价值的类固醇节约替代品,改善了患者的结果和生活质量.